---
$id: https://graph.org.ai/products/commodity/51183404
$type: Product
source: UNSPSC
code: "51183404"
title: "Repaglinide"
class: "51183400"
classTitle: "Antidiabetic and hyperglycemic glinides"
family: "51180000"
familyTitle: "Hormones and hormone antagonists"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Repaglinide

**UNSPSC Code**: 51183404
**Class**: [Antidiabetic and hyperglycemic glinides](Antidiabetic and hyperglycemic glinides.mdx)
**Family**: [Hormones and hormone antagonists](../Hormones and hormone antagonists.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 668Z8C33LU. European Medicines Agency schedules Repaglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10280MIG. Repaglinide generally arises in the molecular formula C27H36N2O4. The term REPAGLINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, no, 3 1992, list 32.) REPAGLINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule repaglinide under HS 29333999 and SITC 51574. As of Q4 2014, REPAGLINIDE remains US FDA's Preferred Term for this commodity. Repaglinide bears US NLM identifiers UMLS ID C0246689 and NCI Concept Code C47703. SMILES: O=C(NC(C1C(N2CCCCC2)CCCC1)CC(C)C)CC1CC(OCC)C(CC1)C(=O)O.

